Cellebrite DI (NASDAQ:CLBT) Announces Quarterly Earnings Results, Beats Estimates By $0.06 EPS

Cellebrite DI (NASDAQ:CLBT) issued its quarterly earnings data on Thursday. The company reported $0.11 EPS for the quarter, topping analysts’ consensus estimates of $0.05 by $0.06, FiscalAI reports. Cellebrite DI had a net margin of 14.48% and a return on equity of 18.38%. The company had revenue of $131.14 million during the quarter, compared to the consensus estimate of $131.87 million.

Here are the key takeaways from Cellebrite DI’s conference call:

• Q2 ARR and revenue fell short of expectations, with ARR rising 21% to $508 million but missing the low end of guidance. Several large government transactions slipped because of new procurement, foreign-entity permitting, and cloud/AI approval requirements.
• Cellebrite reduced its full-year 2026 outlook to $550 million–$560 million of ARR and $555 million–$561 million of revenue, citing slower Inseyets pricing and expansion, elongated deal cycles, and greater caution around large transactions.
• The company raised its full-year adjusted EBITDA outlook to $153 million–$159 million, or a 28% margin, while maintaining confidence in improving free cash flow as headcount remains essentially flat and FX headwinds eventually ease.
• New products are gaining traction: growth products contributed 25% of the sequential ARR increase, Genesis generated about $400,000 of ARR shortly after its launch, and Guardian secured a first major FedRAMP deal with a seven-figure initial order.
• Shiv Ramji became CEO effective immediately in an accelerated succession from Tom Hogan, reflecting the board’s preference for a product-centric leader focused on cloud-native platforms and AI; Cellebrite said the transition has the support of the management team.

Cellebrite DI Price Performance

NASDAQ:CLBT traded up $0.34 during trading hours on Friday, reaching $11.14. The company had a trading volume of 7,835,542 shares, compared to its average volume of 2,139,398. Cellebrite DI has a 1-year low of $9.58 and a 1-year high of $19.98. The business’s 50 day moving average price is $14.52 and its 200-day moving average price is $14.05. The firm has a market cap of $2.78 billion, a PE ratio of 39.79, a price-to-earnings-growth ratio of 1.89 and a beta of 1.18.

Key Headlines Impacting Cellebrite DI

Here are the key news stories impacting Cellebrite DI this week:

• Positive Sentiment: Analysts continue to see upside despite reducing their estimates. JPMorgan lowered its price target from $20 to $16 while retaining an Overweight rating; D.A. Davidson cut its target from $22 to $15 but maintained Buy; and Needham reduced its target from $15 to $12.50 while also keeping a Buy rating. The revised targets remain above the recent trading level. Analyst price-target updates
• Positive Sentiment: Second-quarter adjusted EPS of $0.11 exceeded the commonly cited analyst estimate of $0.05, and subscription revenue continued to grow. Management also raised its adjusted EBITDA target, providing some support for profitability. Cellebrite earnings release
• Positive Sentiment: Unusually heavy call-option activity, with nearly 20,000 contracts traded versus average volume of about 586, suggests some traders are positioning for a rebound. This is a speculative signal rather than a change in fundamentals.
• Neutral Sentiment: Cellebrite completed a planned CEO succession, appointing Shiven Ramji to replace Thomas E. Hogan. The transition could lead to a strategic reset, but it also adds uncertainty as investors reassess the company’s growth plans. CEO succession announcement
• Negative Sentiment: The primary catalyst for the decline was weaker forward guidance. Third-quarter revenue is forecast at $145 million-$148 million, below the $150.3 million consensus, while full-year revenue guidance of $555 million-$561 million trails the $568.1 million estimate. Cellebrite also reduced its 2026 annual recurring revenue outlook, signaling slower growth.
• Negative Sentiment: Revenue of $131.14 million slightly missed expectations of $131.87 million, and ARR reportedly fell short of prior guidance. The revenue and recurring-revenue misses outweighed the quarterly EPS beat. Cellebrite Q2 earnings analysis
• Negative Sentiment: Multiple law firms announced investigations into potential securities-law violations and whether previous projections and disclosures were accurate. These are allegations, not findings, but they increase legal and reputational risk. Cellebrite investigation notice
• Negative Sentiment: Outgoing CEO Thomas Hogan sold 139,713 shares worth approximately $2.15 million, reducing his holdings by about 15%. While the sale may reflect the leadership transition or personal financial planning, its timing weighs on investor sentiment. SEC insider trading filing

Insider Activity at Cellebrite DI

In other Cellebrite DI news, CRO Marcus Jewell sold 12,658 shares of the company’s stock in a transaction on Monday, May 18th. The shares were sold at an average price of $12.77, for a total transaction of $161,642.66. Following the completion of the transaction, the executive directly owned 440,101 shares in the company, valued at approximately $5,620,089.77. This represents a 2.80% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CFO David Barter sold 41,734 shares of the firm’s stock in a transaction dated Wednesday, July 8th. The shares were sold at an average price of $16.38, for a total transaction of $683,602.92. Following the completion of the transaction, the chief financial officer directly owned 334,219 shares in the company, valued at $5,474,507.22. This represents a 11.10% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 297,934 shares of company stock worth $4,631,972. 5.70% of the stock is owned by company insiders.

Institutional Investors Weigh In On Cellebrite DI

A number of large investors have recently made changes to their positions in the stock. Towarzystwo Funduszy Inwestycyjnych PZU SA increased its stake in shares of Cellebrite DI by 81.0% in the 4th quarter. Towarzystwo Funduszy Inwestycyjnych PZU SA now owns 1,900 shares of the company’s stock worth $34,000 after acquiring an additional 850 shares during the last quarter. Advisory Services Network LLC purchased a new stake in shares of Cellebrite DI in the third quarter valued at about $40,000. Vestcor Inc acquired a new stake in Cellebrite DI during the third quarter worth about $70,000. Pacer Advisors Inc. raised its stake in Cellebrite DI by 45.1% during the fourth quarter. Pacer Advisors Inc. now owns 3,981 shares of the company’s stock worth $72,000 after purchasing an additional 1,238 shares during the period. Finally, Barclays PLC boosted its holdings in Cellebrite DI by 131.5% in the 4th quarter. Barclays PLC now owns 6,305 shares of the company’s stock valued at $114,000 after purchasing an additional 3,582 shares during the last quarter. 45.88% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on CLBT. Lake Street Capital lowered their price objective on Cellebrite DI from $21.00 to $15.00 and set a “buy” rating for the company in a research report on Friday. DA Davidson reduced their target price on Cellebrite DI from $22.00 to $15.00 and set a “buy” rating on the stock in a research report on Friday. Weiss Ratings upgraded Cellebrite DI from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Monday, May 18th. Needham & Company LLC lowered their price target on Cellebrite DI from $15.00 to $12.50 and set a “buy” rating for the company in a report on Friday. Finally, JPMorgan Chase & Co. dropped their price target on Cellebrite DI from $20.00 to $16.00 and set an “overweight” rating on the stock in a research note on Friday. Five investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $16.70.

About Cellebrite DI

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.